Cancer in Heart Disease Patients: What are the Limitations in the Treatment strategy?

Mistiaen, Wilhelm

doi:10.2217/fca.13.33

Cited by 10 publications

(7 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A significantly increased rate of acute coronary syndromes (up to threefold) has been reported among patients with cancer, especially those with active malignancy 13 . The hypercoagulative state, increased bleeding risks, and the probable need for withholding antiplatelet agents are some of the main challenges encountered in choosing the optimal management strategy 14,15 …”

Section: Purposementioning

confidence: 99%

See 1 more Smart Citation

Cardio‐oncology discipline: focus on the necessities in developing countries

et al. 2020

View full text Add to dashboard Cite

Cardiovascular diseases constitute one of the main aetiologies of mortality among patients with cancer. Population ageing and cancer survival rate improvements have resulted in the coexistence of cardiovascular diseases and malignancies in an increasing number of patients. With the diversity in treatments and the introduction of new drug lines, multiple mechanisms of cardiovascular injury have been recognized in these patients. Cardio-oncology is an emerging entity introduced to provide a proper solution to the several challenges encountered in the management of patients with cancer and cardiac involvement. This review will assess the logical grounds for establishing a cardio-oncology unit, describe the main objectives and the detailed responsibilities in such systems, and outline the target population. Furthermore, the importance of research and appropriate data collection will be highlighted. Lastly, the special considerations and modifications required for setting up such centres in the developing countries are discussed.

show abstract

Section: Purposementioning

confidence: 99%

“…13 The hypercoagulative state, increased bleeding risks, and the probable need for withholding antiplatelet agents are some of the main challenges encountered in choosing the optimal management strategy. 14,15 Logistics and requirements…”

mentioning

confidence: 99%

Cardio‐oncology discipline: focus on the necessities in developing countries

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Türk kardiyoloji derneği, American Heart Association (AHA) ve American college of cardiology foundation (ACC) kalp hastalıklarında kalp dışı cerrahi için bir tavsiye tablosu hazırlamış ve uydukları kriterleri ilan etmiştir (Tablo 18-19). Koroner arter hastalıklarının tedavisinde stent uygulaması gerekiyorsa ilaç kaplı stentlerin kullanılmasından (torasik cerrahiyi bir yıl civarında geciktireceği için) kaçınılmalıdır (31). Daha önce kanser tedavisi olmuş hastaların kardiyak tedavisindeki başarı, kanser ve kalp tedavisi arasın-daki intervalin uzunluğuyla doğru orantılıdır.…”

Section: Eş Zamanli Operasyonlarunclassified

Sımultaneous Lung Cancer And Heart Dısease

Okay¹

2016

Toraks Cer Bult

View full text Add to dashboard Cite

Worldwide, especially in developed countries, prolonged life expectancy results in increasing number of age-related / associated diseases like diabetes mellitus, cardiovascular diseases, malignancies, neurological diseases, organ failures etc. in the community. Beside the numbers, planning and applying the treatment of pulmonary and cardiovascular diseases simultaneously in such patients is stil a major challenge. The knowledge and experience gained from the increasing number of patients all over the world led to the conclusion that it could be possible to treat some patient groups who would be considered as difficult or impossible to cure in the past. In this paper we evaluated the treatment process in lung diseases (especially malignancies) and cardiovascular disease seen simultaneously.Keywords: Lung cancer, heart disease, coronary artery disease, pulmonary surgery, concurrent heart lung disease, concurrent heart lung surgery ÖzetÖzellikle batıda olmak üzere tüm dünyada uzayan ortalama ömür süresi, yaşa bağlı/ilintili hastalıkların da toplumda daha sık görülmesi sonucunu doğurmaktadır. Bunlar diyabet, kalp damar hastalıkları, maligniteler, nörolojik hastalıklar, organ yetmezlikleri gibi hastalıklardır. Bu durumun yarattığı sorunlardan biri de eş zamanlı olarak görülen akciğer ve kalp damar hastalıklarının tedavisinin planlanması ve uygulanmasıdır. Tüm dünyada giderek artan sayıdaki hastalardan elde edilen bilgi ve deneyimler eskiden çok zor hatta imkansız olarak kabul edilen hasta gruplarında bile tedavi seçenekleri olabileceğini ve başarıyla uygulanabileceğini göstermektedir. Bu yazıda eş zamanlı görülen kalp-damar hastalıkları ve özel-likle maligniteler olmak üzere akciğer hastalıklarındaki tedavi süreçlerini değerlendirdik.Anahtar kelimeler: Akciğer kanseri, kalp hastalığı, koroner arter hastalığı, akciğer cerrahisi, eş zamanlı kalp akciğer hastalığı, eş zamanlı kalp akciğer cerrahisi

show abstract

“…The prevalence of malignancy and coronary heart disease among male patients was about 7% [1][2][3]. The presence of malignancy in cardiovascular series ranged between 1.9 and 4.2%, and cardiovascular disease was present in 25% of malignant patients [4][5][6][7]. Meanwhile, radio-and chemo-therapy in malignancy also impacted the heart [8].…”

Section: Introductionmentioning

confidence: 99%

Coronary artery bypass grafting in patients with malignancy: a single-institute case series of eight patients

Zhang

et al. 2022

BMC Surg

View full text Add to dashboard Cite

Background The surgical strategy among patients with malignancy and coronary artery disease (CAD) remains controversial. In this study, we present the experiences of coronary artery bypass grafting (CABG) in patients with malignancy and analyzed the treatment outcomes. Methods From January 2011 to October 2021, eight patients combined with coronary artery disease and malignancy, six of them with three-vessel disease and two with anterior descending branch lesions on coronary angiography. The age ranged from 54 to 73 years (61.8 ± 7.7years). Four patients underwent CABG and staging for surgical oncology, and 2 patients underwent CABG and surgical oncology simultaneously. Four patients underwent CABG procedure with cardiopulmonary bypass (on-pump CABG), and the other patients underwent the procedure without cardiopulmonary bypass (off-pump CABG). All patients were followed up for 3 to 96 months (40.4 ± 31.5 months) postoperatively. Results The mean number of grafts was 2.6 ± 1.1, there was no in-hospital death, postoperative myocardial infarction, and stroke. Among the eight patients, one patient received chemotherapy and radiation before bypass surgery, which occurred postoperatively pulmonary infection, and the rest of 7 patients had no major adverse cardiovascular events during follow-up periods. Conclusion Based on the results of the present study, simultaneous or staged CABG and oncologic surgery according to the TNM stage of the tumor and cardiac assessment is an effective treatment for patients with severe CAD combined with malignancy.

show abstract

Cancer in Heart Disease Patients: What are the Limitations in the Treatment strategy?

Cited by 10 publications

References 69 publications

Cardio‐oncology discipline: focus on the necessities in developing countries

Cardio‐oncology discipline: focus on the necessities in developing countries

Sımultaneous Lung Cancer And Heart Dısease

Coronary artery bypass grafting in patients with malignancy: a single-institute case series of eight patients

Contact Info

Product

Resources

About